Jefferies Group’s Arbutus Biopharma ABUS Stock Holding History

Jefferies Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-215,000	Closed	-$4.62M	–	2027
2014 Q1	$4.62M	Buy	+215,000	New	+$3.86M	0.04%	327

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jefferies Group's ABUS Position: Q2 2021 in Review

Jefferies Group sold out of Arbutus Biopharma (ABUS) in Q2 2021, closing a stake of 14,100 shares — an estimated $47K sold.

Jefferies Group first reported a position in ABUS in Q2 2016 and held it in 5 quarters. The position peaked at $47K in Q1 2021. 91 funds tracked by Wall St. Rank hold ABUS as of Q2 2021.

Jefferies Group reported no remaining Arbutus Biopharma position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 14,100 Arbutus Biopharma shares in Q2 2021, an estimated $47K.
Jefferies Group first reported a position in Arbutus Biopharma in Q2 2016 and held it in 5 quarters.
Jefferies Group's Arbutus Biopharma position peaked at $47K in Q1 2021.
91 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.